WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in Brazil will grow from $200 million in 2008 to more than $315 million in 2013. The 2008 market leaders were the tumor necrosis factor-alpha (TNF-alpha) inhibitors Abbott's Humira and Schering-Plough's Remicade which recorded sales of $50 million and $43 million, respectively, despite a combined patient share of two percent. Wyeth's Enbrel, the third marketed agent from this class, recorded fewer sales because of its inconvenient dosing frequency and its availability only in a lyophilized form.
The new Emerging Markets report entitled Rheumatoid Arthritis in Brazil also finds that survey results of Brazilian rheumatologists show regional differences in their preferences for agents within key drug classes for rheumatoid arthritis. While Enbrel emerges as the patient share leader among biologics in Rio de Janeiro, rheumatologists from Sao Paulo and Belo Horizonte prefer Humira and Remicade, respectively.
"Competition among TNF-alpha inhibitors is influenced by a drug's clinical profile, order of market entry, ease of access in the public sector, patients' socioeconomic status, ease of administration and marketing campaigns," stated Irene Koulinska, Sc.D., M.D.
The new report is part of an expansion of the Emerging Markets report series to cover Brazil. The series contains primary research of physicians and epidemiology study in key pharmaceutical markets of Brazil--Rio de Janeiro, Sao Paulo and Belo Horizonte.
About Emerging Markets Reports
Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Gisselle Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 firstname.lastname@example.org email@example.com
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved